Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
194.66
+3.77 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...
Via
Talk Markets
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
The big pharma company's top drug is losing ground, but its dividend keeps rising.
Via
The Motley Fool
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
June 30, 2024
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron.
Via
Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
June 17, 2024
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...
Via
Benzinga
Evaluating BeiGene: Insights From 6 Financial Analysts
April 24, 2024
Via
Benzinga
4 Analysts Assess BeiGene: What You Need To Know
March 27, 2024
Via
Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
7 Large-Cap Stocks That Can Jump 50% By 2025
May 29, 2024
It isn't easy to find large-cap stocks offering 50% upside but that's exactly what this list provides for investors.
Via
InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
May 26, 2024
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto.
Via
Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
BGNE stock results show that BeiGene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
April 28, 2024
Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.
Via
Benzinga
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
April 23, 2024
Via
Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
March 30, 2024
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because...
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
March 22, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...
Via
Benzinga
Exposures
Product Safety
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...
Via
Benzinga
Exposures
Product Safety
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
February 16, 2024
This development comes at a time when the city is grappling with a declining market.
Via
Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
February 13, 2024
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.
Via
InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
February 06, 2024
BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.
Via
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
January 10, 2024
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
HBM Gets Health Boost From Drug Licensing Deals
December 22, 2023
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05...
Via
Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
November 25, 2023
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...
Via
Talk Markets
7 Biotech Stocks to Buy for Big-Time Gains
November 10, 2023
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.